Giant neurofibroma around the knee in a 34-year-old male: a case report
DOI:
https://doi.org/10.18203/2349-2902.isj20262488Keywords:
Neurofibromatosis type 1, Neurofibroma,, Knee mass, Surgical excision, Peripheral nerve sheath tumor, Case reportAbstract
Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disorder characterized by multiple neurofibromas, café-au-lait macules, and skeletal abnormalities. Plexiform neurofibromas can attain large sizes, causing functional impairment and cosmetic deformity. Surgical excision remains the primary treatment for symptomatic lesions. A 34-year-old male with a known history of NF1 presented to the General Surgery OPD with a progressively enlarging mass around the left knee and multiple swellings over the body for 15 years. The swelling around left knee was associated with discomfort during walking and restriction of knee movements. Physical examination revealed a large, soft-to-firm, non-tender mass measuring approximately 10×12 cm involving the anterior aspect of the knee. Magnetic resonance imaging (MRI) of left knee suggested a large soft tissue mass consistent with neurofibroma without intra-articular extension. CECT Chest suggested few apical bullas and multiple cutaneous fibromas. The patient underwent complete surgical excision of the mass under general anaesthesia. Histopathological examination confirmed the diagnosis of neurofibroma. The postoperative period was uneventful, and the patient showed significant functional improvement during follow-up. Giant neurofibromas around the knee are uncommon and can significantly impair mobility. Early diagnosis and complete surgical excision can provide symptomatic relief, improve function, and prevent further complications.
References
Miller DT, Freedenberg D, Schorry E, Ullrich NJ, Viskochil D, Korf BR, et al. Health Supervision for Children with Neurofibromatosis Type 1. Pediatrics. 2019;143(5):e20190660.
Legius E, Messiaen L, Wolkenstein P, Pancza P, Avery RA, Berman Y, et al. Revised Diagnostic Criteria for Neurofibromatosis Type 1 and Legius Syndrome: An International Consensus Recommendation. Genetics Med. 2021;23(8):1506-13.
Moodley M, Robles Lopez K. Neurofibromatosis Type 1-An Update. Seminars Pediat Neurol. 2024;52:101172.
Botero V, Tomchik SM. Unraveling Neuronal and Metabolic Alterations in Neurofibromatosis Type 1. J Neurodevelopmental Disord. 2024;16:49.
Rana S, Low CE, Karthikeyan M, Koh MJA, Ngeow J, Chiang J. A Systematic Review of Diagnostic Modalities and Strategies for the Assessment of Complications in Adult Patients with Neurofibromatosis Type 1. Cancers (Basel). 2024;16(6):1119.
Dombi E, Baldwin A, Marcus LJ, Fisher MJ, Weiss B, Kim A, et al. Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. N Eng J Med. 2020;382(15):1430-42.
Armstrong AE, Belzberg AJ, Crawford JR, Hirbe AC, Wang ZJ, et al. Treatment Decisions and the Use of MEK Inhibitors for Children with Neurofibromatosis Type 1-Related Plexiform Neurofibromas. BMC Cancer. 2023;23(1):553.
Plotkin SR, Blakeley JO, Evans DG, Hanemann CO, Hulsebos TJM, Hunter-Schaedle K, et al. Update from the 2021 International Consensus Conference on Neurofibromatosis and Schwannomatosis. Neurology. 2022;98(18):e1835-47.
WHO Classification of Tumours Editorial Board. Soft Tissue and Bone Tumours. 5th ed. Lyon, France: International Agency for Research on Cancer (IARC). 2020.
Fisher MJ, Weiss BD, Tonsgard JH, Gutmann DH, Schorry EK, Ullrich NJ, et al. Management of Neurofibromatosis Type 1-Associated Plexiform Neurofibromas. Neuro-Oncol. 2022;24(11):1827-40.